NZ766005A - Factor h binding protein variants and methods of use thereof - Google Patents

Factor h binding protein variants and methods of use thereof

Info

Publication number
NZ766005A
NZ766005A NZ766005A NZ76600515A NZ766005A NZ 766005 A NZ766005 A NZ 766005A NZ 766005 A NZ766005 A NZ 766005A NZ 76600515 A NZ76600515 A NZ 76600515A NZ 766005 A NZ766005 A NZ 766005A
Authority
NZ
New Zealand
Prior art keywords
factor
methods
binding protein
amino acid
proteins
Prior art date
Application number
NZ766005A
Other languages
English (en)
Inventor
Peter T Beernink
Original Assignee
Children’S Hospital & Res Center At Oakland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Children’S Hospital & Res Center At Oakland filed Critical Children’S Hospital & Res Center At Oakland
Publication of NZ766005A publication Critical patent/NZ766005A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ766005A 2014-07-23 2015-07-22 Factor h binding protein variants and methods of use thereof NZ766005A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462028123P 2014-07-23 2014-07-23
NZ729206A NZ729206A (en) 2014-07-23 2015-07-22 Factor h binding protein variants and methods of use thereof

Publications (1)

Publication Number Publication Date
NZ766005A true NZ766005A (en) 2024-03-22

Family

ID=55163727

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ729206A NZ729206A (en) 2014-07-23 2015-07-22 Factor h binding protein variants and methods of use thereof
NZ766005A NZ766005A (en) 2014-07-23 2015-07-22 Factor h binding protein variants and methods of use thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ729206A NZ729206A (en) 2014-07-23 2015-07-22 Factor h binding protein variants and methods of use thereof

Country Status (15)

Country Link
US (10) US10266572B2 (OSRAM)
EP (2) EP3172224B1 (OSRAM)
JP (4) JP6796057B2 (OSRAM)
KR (2) KR102752259B1 (OSRAM)
CN (3) CN106715464B (OSRAM)
AU (5) AU2015292615B2 (OSRAM)
BR (1) BR112017001417B1 (OSRAM)
CA (2) CA3212723A1 (OSRAM)
CO (1) CO2017000558A2 (OSRAM)
CR (1) CR20170020A (OSRAM)
ES (1) ES2922554T3 (OSRAM)
MX (3) MX382409B (OSRAM)
NZ (2) NZ729206A (OSRAM)
RU (1) RU2714248C2 (OSRAM)
WO (1) WO2016014719A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2661569T3 (es) 2010-03-30 2018-04-02 Children's Hospital & Research Center At Oakland Proteínas de unión al factor H (fHbp) con propiedades alteradas y métodos de uso de las mismas
ES2922554T3 (es) 2014-07-23 2022-09-16 Childrens Hospital & Res Center At Oakland Variantes de proteínas de unión al factor H y métodos de uso de las mismas
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
WO2018093176A2 (ko) 2016-11-16 2018-05-24 주식회사 케이엠더블유 적층구조의 mimo 안테나 어셈블리
KR101854309B1 (ko) 2016-11-16 2018-05-03 주식회사 케이엠더블유 Mimo 안테나 어셈블리
US11542467B2 (en) * 2017-12-04 2023-01-03 Intravacc B.V. Process for producing outer membrane vesicles
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
GB202016604D0 (en) 2020-10-20 2020-12-02 Univ Of Oxford Compositions and methods for inducing an immune response
TW202245836A (zh) 2021-02-19 2022-12-01 美商賽諾菲巴斯德公司 重組ｂ型腦膜炎球菌疫苗
TW202423477A (zh) 2022-08-03 2024-06-16 美商賽諾菲巴斯德公司 針對腦膜炎奈瑟氏菌b的含佐劑免疫原性組成物

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
EP0812593B8 (en) 1993-03-23 2010-11-10 SmithKline Beecham Biologicals S.A. Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
US6339068B1 (en) 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
TR200002930T2 (tr) 1998-04-09 2000-12-21 Smithkline Beecham Biologicals S.A. Kolaylaştırıcı kompozisyonlar
US20070026021A1 (en) 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions
MX343752B (es) 1998-05-01 2016-11-22 Novartis Vaccines & Diagnostics Inc Antigenos de neisseria meningitidis y composiciones que los contienen.
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
US7357936B1 (en) 1998-10-16 2008-04-15 Smithkline Beecham Biologicals, Sa Adjuvant systems and vaccines
EP1162999B1 (en) 1999-03-19 2006-11-29 Glaxosmithkline Biologicals S.A. Vaccine against Streptococcus pneumoniae
WO2000062800A2 (en) 1999-04-19 2000-10-26 Smithkline Beecham Biologicals Sa Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
IL148672A0 (en) 1999-09-24 2002-09-12 Smithkline Beecham Biolog Use of combination of polyxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
AU766635B2 (en) 1999-09-24 2003-10-23 Smithkline Beecham Biologicals (Sa) Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
AU1917501A (en) 1999-11-12 2001-06-06 University Of Iowa Research Foundation, The Control of neisserial membrane synthesis
AU2013206190A1 (en) 1999-11-29 2013-06-27 Novartis Vaccines And Diagnostics S.R.L. Compositions comprising Neisseria meningitidis antigens from serogroups B and C as well as a further antigen
NZ520466A (en) 2000-01-17 2003-09-26 Chiron S Outer membrane vesicle (OMV) vaccine comprising n. meningitidis serogroup B outer membrane proteins
ATE503837T1 (de) 2000-02-28 2011-04-15 Novartis Vaccines & Diagnostic Hybride expression neisserscher proteine
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
US6839862B2 (en) 2001-05-31 2005-01-04 Koninklijke Philips Electronics N.V. Parallel data communication having skew intolerant data groups
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
ATE492288T1 (de) * 2002-10-11 2011-01-15 Novartis Vaccines & Diagnostic Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
WO2004074433A2 (en) 2003-01-30 2004-09-02 Yale University Rag polypeptides, nucleic acids, and their use
JP5173194B2 (ja) * 2003-12-23 2013-03-27 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
MX2007008785A (es) 2005-01-27 2008-02-15 Childrens Hosp & Res Ct Oak Vacunas de vesicula basadas en gna1870 para proteccion de amplio espectro contra padecimientos causados por neisseria meningitidis.
CN101160412A (zh) 2005-02-14 2008-04-09 爱荷华大学研究基金会 治疗和诊断年龄相关性黄斑变性的方法和试剂
GB0510790D0 (en) 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
WO2009038889A1 (en) 2007-08-02 2009-03-26 Children's Hospital And Research Center At Oakland Fhbp- and lpxl1-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
US9579372B2 (en) * 2008-02-21 2017-02-28 Glaxosmithkline Biologicals Sa Meningococcal fHBP polypeptides
EP2631245A1 (en) 2008-03-10 2013-08-28 Children's Hospital & Research Center at Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
US8476032B2 (en) 2008-08-27 2013-07-02 Children's Hospital & Research Center Oakland Complement factor H-based assays for serum bactericidal activity against Neisseria meningitidis
US8470340B2 (en) 2008-09-03 2013-06-25 Children's Hospital & Research Center Oakland Peptides presenting an epitope of a domain of factor H binding protein and methods of use
IT1394288B1 (it) 2008-09-12 2012-06-06 Novartis Vaccines & Diagnostic Immunogeni di proteine che legano il fattore h.
GB0819633D0 (en) * 2008-10-25 2008-12-03 Isis Innovation Composition
HRP20201076T1 (hr) 2009-03-24 2020-10-30 Glaxosmithkline Biologicals Sa Adjuvantni vezujući protein meningokokalnog faktora h
WO2010127172A2 (en) 2009-04-30 2010-11-04 Children's Hospital & Research Center At Oakland Chimeric factor h binding proteins (fhbp) and methods of use
AU2010310985B2 (en) * 2009-10-27 2014-11-06 Glaxosmithkline Biologicals S.A. Modified meningococcal fHBP polypeptides
ES2661569T3 (es) * 2010-03-30 2018-04-02 Children's Hospital & Research Center At Oakland Proteínas de unión al factor H (fHbp) con propiedades alteradas y métodos de uso de las mismas
CA2809758C (en) * 2010-09-10 2021-07-13 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
CN102028941B (zh) 2011-02-11 2013-02-13 中国医学科学院医学生物学研究所 一种b群脑膜炎球菌重组蛋白嵌合疫苗及其制备方法
US9272006B2 (en) 2011-07-07 2016-03-01 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Ministerie Van Volksgezondheid, Welzijn En Sport Process for detergent-free production of outer membrane vesicles of a gram-negative bacterium
WO2013078223A1 (en) 2011-11-23 2013-05-30 Children's Hospital & Research Center Oakland Anti-factor h binding protein antibodies and methods of use thereof
MX351993B (es) * 2012-03-09 2017-11-03 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
GB201215005D0 (en) 2012-08-23 2012-10-10 Isis Innovation Stabilised meningitis vaccine
JP2016527278A (ja) * 2013-08-02 2016-09-08 チルドレンズ ホスピタル アンド リサーチ センター オークランド 天然に生じないｈ因子結合タンパク質（ｆｈｂｐ）及びその使用の方法
SG10201907875TA (en) 2014-02-28 2019-09-27 Glaxosmithkline Biologicals Sa Modified meningococcal fhbp polypeptides
KR20150128099A (ko) 2014-05-08 2015-11-18 (주)엘지하우시스 Pla 및 pha 혼합수지를 이용한 벽지 및 그 제조 방법
CN107349423B (zh) * 2014-06-24 2021-03-19 上海生物制品研究所有限责任公司 一种脑膜炎球菌抗原组合及其应用
AR102324A1 (es) * 2014-07-17 2017-02-22 Glaxosmithkline Biologicals Sa Polipéptidos fhbp (proteína de unión al factor h) meningocócicos modificados
ES2922554T3 (es) 2014-07-23 2022-09-16 Childrens Hospital & Res Center At Oakland Variantes de proteínas de unión al factor H y métodos de uso de las mismas
EP3607967A1 (en) * 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides

Also Published As

Publication number Publication date
CN106715464B (zh) 2021-03-16
US20250154206A1 (en) 2025-05-15
AU2019264600B2 (en) 2021-04-01
US11673920B2 (en) 2023-06-13
US10266572B2 (en) 2019-04-23
JP2025108722A (ja) 2025-07-23
US20200095288A1 (en) 2020-03-26
US10995122B2 (en) 2021-05-04
CA2955802A1 (en) 2016-01-28
EP4074726A3 (en) 2022-11-23
JP6796057B2 (ja) 2020-12-02
US20240025951A1 (en) 2024-01-25
US10487122B2 (en) 2019-11-26
KR102752259B1 (ko) 2025-01-13
US12129282B2 (en) 2024-10-29
MX2023000204A (es) 2023-02-09
CA2955802C (en) 2023-10-31
RU2020105192A (ru) 2020-02-12
NZ766003A (en) 2024-01-26
JP2021000121A (ja) 2021-01-07
AU2019264600A1 (en) 2019-12-05
US20210101942A1 (en) 2021-04-08
CO2017000558A2 (es) 2017-06-20
KR20230155595A (ko) 2023-11-10
US20250136648A1 (en) 2025-05-01
CN106715464A (zh) 2017-05-24
EP3172224A4 (en) 2018-04-18
KR102761870B1 (ko) 2025-02-05
JP2017522877A (ja) 2017-08-17
WO2016014719A1 (en) 2016-01-28
US11834476B2 (en) 2023-12-05
MX382409B (es) 2025-03-13
CN112851768A (zh) 2021-05-28
CR20170020A (es) 2017-08-10
BR112017001417A2 (pt) 2017-11-21
RU2017104742A (ru) 2018-08-29
US10836799B2 (en) 2020-11-17
AU2023204391A1 (en) 2023-08-03
BR112017001417B1 (pt) 2023-11-07
AU2023204391B2 (en) 2025-01-23
EP3172224B1 (en) 2022-06-29
US20190225655A1 (en) 2019-07-25
EP3172224A1 (en) 2017-05-31
MX2021005373A (es) 2021-07-06
US20200109179A1 (en) 2020-04-09
AU2015292615B2 (en) 2019-10-24
US20240101610A1 (en) 2024-03-28
RU2714248C2 (ru) 2020-02-13
EP4074726A2 (en) 2022-10-19
AU2015292615A1 (en) 2017-03-16
ES2922554T3 (es) 2022-09-16
CA3212723A1 (en) 2016-01-28
NZ766444A (en) 2024-01-26
US20210340191A1 (en) 2021-11-04
CN119613509A (zh) 2025-03-14
JP2023011916A (ja) 2023-01-24
US20170183384A1 (en) 2017-06-29
NZ729206A (en) 2022-07-01
AU2021203828A1 (en) 2021-07-08
JP7719046B2 (ja) 2025-08-05
US12269849B2 (en) 2025-04-08
RU2017104742A3 (OSRAM) 2019-02-27
KR20170028442A (ko) 2017-03-13
JP7221917B2 (ja) 2023-02-14
MX2017001038A (es) 2018-02-09
AU2025202774A1 (en) 2025-05-08
AU2021203828B2 (en) 2023-04-13

Similar Documents

Publication Publication Date Title
NZ766005A (en) Factor h binding protein variants and methods of use thereof
PH12018501882A1 (en) Binding proteins and methods of use thereof
BR122021020829B8 (pt) Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada
WO2015112886A3 (en) Binding proteins and methods of use thereof
MY200335A (en) Bispecific binding proteins and uses thereof
MX2018000147A (es) Moleculas de anticuerpo que se unen al grupo de diferenciacion 45 (cd45).
WO2018083087A3 (en) Binding proteins
EA035991B9 (ru) Новый полисахарид и его применения
MX2018000590A (es) Moleculas de anticuerpo que se unen a agrupacion de diferenciacion 79 (cd79).
MX357193B (es) Moleculas de union anti-alfa sinucleina.
WO2015112749A3 (en) Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
MA40527A (fr) Protéines de liaison à l'antigène se liant à wisp5
WO2014136064A3 (en) Immunogenic fusion polypeptides
MX2016000393A (es) Modificaciones de proteinas quimioenzimaticas de lisina utilizando transglutaminasa microbiana.
MX2015000754A (es) Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos.
WO2017019957A3 (en) Binding proteins and methods of use thereof
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
WO2019094533A8 (en) Angptl8-binding agents and methods of use thereof
MX2016001412A (es) Proteinas de union al factor h (fhbp) de origen no natural y métodos de uso de estas.
PH12019502449A1 (en) Anti-jagged1 antigen binding proteins
MX2016014726A (es) Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.
EP4074830A3 (en) Immunogenic compositions and vaccines derived from bacterial surface receptor proteins
IN2014CN00547A (OSRAM)
MX2015004892A (es) Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21.
ZA202201468B (en) Method

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 JUL 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240704

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 JUL 2026 BY COMPUTER PACKAGES INC

Effective date: 20250630